Difference between revisions of "PDFF Biomarker Ctte"
Jump to navigation
Jump to search
(5 intermediate revisions by the same user not shown) | |||
Line 10: | Line 10: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
− | <br /> | + | <br />Notes are posted after they are approved by the PDFF BC during the following t-con. The last meeting was on February 3, 2022. |
− | *[[Media: | + | *[[Media:2021_04-01_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|April 1, 2021]] |
− | *[[Media: | + | *[[Media:2021_02-04_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|February 4, 2021]] |
− | *[[Media: | + | *[[Media:2021_01-07_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|January 7, 2021]] |
'''''[[PDFF Biomarker Committee Call Summaries Archive]]''''' | '''''[[PDFF Biomarker Committee Call Summaries Archive]]''''' |
Latest revision as of 14:53, 7 February 2022
- Co-chairs: Scott Reeder, MD, PhD, Takeshi Yokoo, MD, PhD
- RSNA Staff Support: Susan Stanfa
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF.
Meetings
Approved call summaries:
Notes are posted after they are approved by the PDFF BC during the following t-con. The last meeting was on February 3, 2022.
PDFF Biomarker Committee Call Summaries Archive